Bank Julius Baer & Co’s Filana Therapeutics FLNA Stock Holding History

Bank Julius Baer & Co’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-400	Closed	-$17K	–	765
2021 Q4	$17K	Buy	+400	New	+$21K	﹤0.01%	756
2021 Q3	–	Sell	-11,002	Closed	-$940K	–	856
2021 Q2	$940K	Sell	11,002 -498	-4%	-$26.7K	0.01%	356
2021 Q1	$517K	Buy	+11,500	New	+$452K	﹤0.01%	440

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bank Julius Baer & Co's FLNA Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 400 shares — an estimated $17K sold.

Bank Julius Baer & Co first reported a position in FLNA in Q1 2021 and held it in 3 quarters. The position peaked at $940K in Q2 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

Bank Julius Baer & Co reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
Bank Julius Baer & Co sold 400 Filana Therapeutics shares in Q1 2022, an estimated $17K.
Bank Julius Baer & Co first reported a position in Filana Therapeutics in Q1 2021 and held it in 3 quarters.
Bank Julius Baer & Co's Filana Therapeutics position peaked at $940K in Q2 2021.
163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.